Though testosterone treatment improves bone strength and structure, a large study on older hypogonadal men showed a high risk for fracture with the treatment.
For men with hypogonadism and low prostate cancer risk, TRT didn't increase the risk for prostate adverse events, said a new analysis likely to inform decision-making.
A large randomized controlled trial found that testosterone replacement therapy did not increase the risk for prostate cancer in middle-aged and older men with hypogonadism.